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1. INTRODUCTION 
1.1. Characteristics of the inflammatory skin disease, psoriasis 
Plaque-type psoriasis (also known as Psoriasis vulgaris) is a chronic inflammatory, 
multifactorial, immune-mediated skin disease, characterized by dry, red, scaly patches and 
affects 1–3% of the global population. The pathogenesis of this complex disease is only 
partially understood, and currently only symptomatic treatments are available. Major 
characteristics of psoriatic plaques are hyperproliferation and altered differentiation of 
keratinocytes coupled with massive immune-cell infiltration. Secreted cytokines and 
chemokines are believed to key mediators of the initiation of the disease. The onset of 
symptoms is presumably triggered by an overreaction of the immune system. This is followed 
by the response of keratinocytes to cytokines by proliferation, activation and secretion of 
proinflammatory mediators (cytokines, chemokines, antimicrobial peptides) which help to 
amplify the inflammatory process. Based on age, as well as genetic and immunopathogenic 
characteristics, chronic plaque type psoriasis has two distinct subtypes: early and late onset 
psoriasis. Early onset psoriasis presents at or before 40 years of age and affects 75% of patients, 
while late onset psoriasis first presents after the age of 40 years and affects 25% of patients.  
Genetic factors play an important role in the pathogenesis of the disease. At least fifteen 
psoriasis susceptible loci (PSORS) have been already discovered in the human genome. 
PSORS1 locus -which located at the region of major histocompatibility complex on 
chromosome 6- is responsible for 30-50% of genetic origin of the disease. On the PSOROS1 
locus, HLA-Cw6 is the most frequently mapped allele in population with early onset of the 
disease. Furthermore, single nucleotide polymorphisms are discovered in fifty different regions 
of the human genome by genome-wide association studies, which are in connection with 
psoriasis. Apart from the genetic factors, environmental effects could also play role in the 
pathogenesis of the disease including stress, physical trauma, smoking and alcohol. 
1.2. Alterations in the non-lesional psoriatic skin 
Alterations in healthy looking non-lesional skin of psoriasis patients have been described, 
which may contribute to the development of the symptoms. In addition to hyperproliferation, 
altered keratinocyte differentiation and massive immune-cell infiltration, the dermal 
extracellular matrix (ECM) and the basement membrane (BM) are also affected in non-lesional 
skin of patients. Non-lesional epidermal keratinocytes have been shown to represent a “pre-
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activated” state for hyperproliferation: these cells are more sensitive to stress and to 
proliferative signals. Alterations of the ECM that are already present in non-lesional skin also 
affect the cell attachment modulator fibronectin (FN), which is differentially expressed in non-
lesional skin. Previously, we found that fibroblasts, as well as basal keratinocytes, express high 
levels of the FN splice variant that contains the extra domain A (EDA+FN) in non-lesional skin. 
Moreover, some integrins, including the FN-interacting α5β1-integrin, also exhibit an increased 
expression in keratinocytes at the dermal–epidermal junction (DEJ). The enhanced EDA+FN 
and α5β1-integrin production that we observed in psoriatic non-lesional skin may contribute to 
the induction of keratinocyte proliferation. Furthermore, at the DEJ in non-lesional skin, the 
laminin layer of the BM is discontinuous and the connection of keratinocytes to the BM is also 
altered. 
To gain further insight into the pathomechanism of psoriasis, we previously performed large-
scale proteomic study in which healthy, psoriatic non-lesional and lesional skin were compared. 
In this study, cartilage oligomeric matrix protein (COMP) exhibited elevated expression in non-
lesional skin in comparison to healthy skin. 
1.3. Structure, functions and interaction partners of COMP 
COMP is a non-collagenous, 524-kDa, homopentameric, glycoprotein component of the 
ECM. It belongs to the family of thrombospondins and often referred to as thrombospondin-5. 
The main functions of thrombospondins are ECM organization and remodeling. The 
homopentameric structure of COMP is formed via the N-terminal coiled-coil domain, resulting 
in a flexible molecule with a bouquet-like form that allows to interact with multiple cellular and 
extracellular components simultaneously.  
COMP is mainly expressed in cartilage, but it also appears in tendon, ligament, synovium, 
vascular smooth muscle cells, cardiomyocytes, activated platelets and skin as well.  
Interaction partners of COMP in the ECM are collagen type I and III and FN, among others. 
Interestingly, the molecules mentioned above are also known to be affected in psoriasis.  
COMP modulates cellular behavior via direct interactions with cell-surface proteins, 
including the α5β1, α7β1 and αvβ3 members of the integrin family. α5β1-integrin modulates 
processes in psoriasis pathogenesis, including inflammatory responses and keratinocyte 
proliferation. 
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1.4. COMP in diseases 
COMP has been associated with several diseases. Autosomal dominant mutations in the 
COMP gene cause skeletal disorders, such as pseudoachondroplasia and multiple epiphyseal 
dysplasia. The presence of COMP in serum and synovial fluid serves as a biomarker in 
inflammatory diseases affecting the cartilage of joints, such as rheumatic disorders including 
rheumatoid and psoriatic arthritis.  
1.5. COMP in the skin 
In healthy skin, COMP is primarily produced by fibroblasts and localizes to the papillary 
dermis where it is believed to take part in ECM stabilization and provide cohesion between the 
anchoring plaques of the upper dermis and the BM. 
COMP accumulation in the dermis is elevated in various skin disorders, including localized 
scleroderma, wounds and exudates of patients with venous leg ulcers, in the fibrotic stroma of 
basal cell carcinoma and skin keloids. Although COMP accumulation in the dermis is elevated 
in several skin disorders, it has not been previously investigated previously in the context of 
psoriasis.  
2. AIMS 
Psoriasis is an inflammatory skin disease, where the non-lesional skin of patients contains 
alterations, which predispose to the development of the symptoms. These alterations affect the 
DEJ region, where the fibronectin splice variant, EDA+FN and α5β1-integrin showed increased 
expression, and the laminin layer within the BM is discontinuous.  
In healthy skin, COMP is localized into the DEJ region, and believed to provide cohesion 
between the anchoring plaques of the upper dermis and the BM. Furthermore, it can directly 
interact with α5β1-integrin and fibronectin as well. Besides, in our previous proteomic study, 
we found elevated COMP protein level in non-lesional skin in comparison to healthy skin. 
Based on these previous results, we aimed to study the potential role of COMP in the 
pathomechanism of psoriasis.  
We aimed to 
- examine the tissue distribution of COMP in the healthy, psoriatic non-lesional and 
lesional skin. 
- determine the protein level of COMP in the healthy, psoriatic non-lesional and lesional 
skin. 
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- determine COMP expression at the mRNA level in healthy and non-lesional cultured 
fibroblasts. 
- study whether COMP accumulation allows interaction with basal keratinocytes through 
the discontinuous BM comparing the healthy and non-lesional skin. 
- further study the DEJ region and examine, whether COMP accumulation allows 
interaction with a potential interaction partner, fibronectin splice variant EDA+ FN -
which is known to influence the behavior of the keratinocytes-, comparing the healthy 
and non-lesional skin. 
- examine whether COMP can affect the behavior of keratinocytes in vitro and ex vivo. 
3. MATERIALS AND METHODS 
3.1. Skin samples and ethics 
Skin punch biopsies (d=6 mm) were collected from healthy volunteers (n=10; age 18–70 
years), and from psoriatic patients with moderate-to-severe chronic plaque-type psoriasis from 
lesional (n=13) and non-lesional skin areas (n=13; minimum of 6 cm from lesional region; age 
18–70 years). Tissue collection was obtained after written informed consent, in accordance with 
the rules of the Helsinki Declaration. The study was confirmed by the Human Investigation 
Review Board of the University of Szeged (PSO-EDAFN-002, 34/2015, 3517, 23 February 
2015, Szeged, Hungary; PSO-ECMPR-002 IF-562-5/2016 and; 157/2015-SZTE, 3638, 21 
September 2015, Hungary). 
3.2. Protein isolation and western blot analysis 
For preparation of tissue protein extracts, skin biopsies (healthy, psoriatic non-lesional and 
psoriatic lesional) were cut into small pieces with a razor blade. 6 M guanidine hydrochloride 
solution was used as an extraction buffer for 24 h at 4°C under continuous agitation. Protein 
extracts (25 μg) were separated on a 4–20% gradient SDS polyacrylamide gel under reducing 
or non-reducing conditions. Proteins were transferred to a nitrocellulose membrane and blocked 
in 5% non-fat milk powder containing Tris-buffered saline (TBS) for 60 min at room 
temperature (RT). Membranes were incubated for overnight at 4°C with anti-human COMP 
and actin primary antibodies. Subsequently, membranes were incubated with horseradish 
peroxidase-conjugated secondary antibodies for 60 min at RT. Signal was visualized with 
Clarity Max Western ECL Substrate on a C-digit blot scanner. 
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3.3. Fluorescence microscopic analysis 
Biopsies were frozen in a cryogenic matrix or were paraffin embedded and were 
subsequently cut into 5 µm sections. For fixation and permeabilization, 4% paraformaldehyde 
followed by 0.25% TritonX-100 or commercially available staining buffer set were used. For 
blocking, TBS containing 1% bovine serum albumin and 1% normal goat serum (NGS) was 
used, and for frozen samples, which were digested with chondroitinase ABC, 10% fetal bovine 
serum (FBS) and 5% NGS were applied. Samples were incubated with the following anti-
human primary antibodies: COMP, β1-integrin, actin, Ki67, keratin-17 (KRT17), laminin 
alpha-1 (LAMA1) and fibronectin (EDA+FN). Isotype controls were the following: rabbit 
polyclonal IgG and mouse IgG1 antibodies. As secondary antibodies, Alexa Fluor (AF) 546 
conjugated anti-rabbit IgG and AF 647 conjugated anti-mouse IgG were used. Nuclei were 
visualized with 4ʹ,6-diamidino-2-phenylindole (DAPI) staining. Zeiss LSM 880 or Zeiss Axio 
Imager Z1 microscopes were used for visualization. 
Pearson’s correlation coefficient, R, was calculated using ImageJ/Fiji software. 
3.4. RNA isolation and real-time RT-PCR 
Total RNA was isolated from primary fibroblasts from healthy and psoriatic non-lesional 
skin cultured in 75 cm2 cell culture flasks and collected at the fifth passage using TRI-Reagent 
as described by the manufacturer. After the RNA isolation cDNA synthesis was performed, 
followed by real-time RT-PCR using COMP and 18S rRNA primers.   
3.5. Cell cultures and examination of cellular properties 
3.5.1. Cell cultures 
Primary dermal fibroblasts were isolated from healthy and psoriatic non-lesional skin 
biopsies, and normal human epidermal keratinocytes (NHEKs) were isolated from healthy skin 
samples. Keratinocytes were obtained from the epidermal part and the cells were then grown in 
keratinocyte serum-free medium supplemented with 1% antibiotic/antimycotic solution 
(AB/AM), brain pituitary extract and epidermal growth factor. Fibroblasts were obtained from 
the dermal part and were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 1 g/l 
glucose, supplemented with 5% FBS, 1% AB/AM and 1% L-glutamine. The human 
immortalized keratinocyte cell line HPV-KER was also used for our experiments. Culture 
conditions of HPV-KER cells are the same as NHEK cells. Each cell type was cultured at 37°C 
in a humidified atmosphere with 5% v/v CO2.   
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3.5.2. Real-time, label-free cellular analysis of HPV-KER cells using the 
xCELLigence system 
xCELLigence is a real-time, impedance measurement-based cellular analysis system, where 
dimensionless Cell Index (CI) value is calculated. This system was used to investigate the effect 
of the COMP protein on keratinocytes. HPV-KER cells were plated at a density of 10,000 
cells/well in uncoated 96-well E-plates or wells that were coated with low-concentration (1 
μg/ml) or high-concentration (10 μg/ml) recombinant human COMP protein (rhCOMP). 
Impedance measurement was performed in every 15 min for 140 h, and a dimension-free CI 
value was calculated for every time point.  
3.5.3. Cell-proliferation assay  
To investigate the effect of COMP on keratinocyte proliferation, a bromodeoxyuridine/5-
bromo-2'-deoxyuridine (BrdU) cell-proliferation colorimetric ELISA assay was performed. 
HPV-KER and NHEK cells were plated at a density of 10,000 cells/well in 96-well plates that 
were uncoated or coated with low- (1 µg/ml) or high-concentration (10 µg/ml) rhCOMP 
protein, in three technical replicates. For the blocking of α5- and β1-integrin, the following 
primary antibodies (1 µg antibody for 106 cells) were used: mouse anti-human α5-integrin 
antibody, mouse anti-human β1-integrin. Goat anti-human COMP antibody (1 µg antibody for 
10 µg/ml rhCOMP protein) was applied to block the COMP protein. Integrin- and COMP-
blocking was applied to cells grown on uncoated plates or plates coated with 10 µg/ml rhCOMP 
protein. BrdU assay was performed at 24 and 72 hours after blocking, according to the 
manufacturer’s instructions. 
3.5.4. Further investigation of keratinocyte cell-proliferation 
To further investigate the effect of COMP on NHEK cell’s proliferation, Ki67 
immunofluorescent staining was applied, using integrin and COMP-blocking as described 
above. Cells were plated at a density of 20,000 cells/well in 8-well chamber slides that were 
uncoated or coated with high-concentration (10 μg/ml) rhCOMP, in three biological replicates. 
Ki67 positive cells were counted on three randomly selected areas per group, and statistical 
analysis was performed. 
3.6. Ex vivo skin wound-healing assay 
Healthy skin samples were collected for the ex vivo organotypic wound healing assay. 
Approximately 1 cm diameter skin pieces were cut and mildly wounded in the middle using a 
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4 mm punch biopsy blade. Wounded skin samples and unwounded control samples were 
incubated for 72 hours at an air–liquid interface on the upper part of transwell cell culture 
inserts. The dermal part was in contact with DMEM F12 culture media supplemented with 10% 
FBS and 1% AB/AM. The middle of the wounds was treated for 72 hours with high-
concentration (10 µg/ml) rhCOMP diluted in phosphate buffered saline (PBS) or PBS only as 
a control. Samples were fixed in formalin and embedded in paraffin for immunofluorescent 
staining. To determine the rate of proliferation, 50 cells on each wound edge were counted and 
the proportion of Ki67 positive cells was determined. Re-epithelization of untreated, control 
(where only PBS was administered), and COMP-treated wounds were assessed by measuring 
the area using the ImageJ software. 
3.7. Hematoxylin eosin staining and light microscopic analysis 
To visualize the tissue structure of ex vivo wound model samples, hematoxylin-eosin staining 
was performed according to the manufacturer’s instructions in a Leica ST5020 Multistainer 
device. The stained samples were visualized with a Nikon eclipse TS100 microscope. 
3.8. Statistical analysis 
For comparing only two groups, two-tailed Student t test was performed. One-way analysis 
of variance (ANOVA) with Tukey post hoc test was used to compare more than two groups. 
Differences were considered statistically significant at **P<0.01, *P<0.05. 
4. RESULTS 
4.1. COMP level is elevated in psoriatic non-lesional skin 
Non-lesional skin carries several known alterations of the ECM in the papillary dermis. 
Since COMP has previously been reported to also be present in the papillary dermis, COMP-
protein accumulation was characterized in non-lesional and lesional skin from psoriasis patients 
and skin from healthy individuals. COMP protein was detected with western blot analysis under 
reducing and non-reducing conditions. Under reducing conditions, we detected elevated COMP 
monomer and fragment levels in psoriatic non-lesional protein extracts, compared to healthy 
skin. 
4.2. COMP deposition is altered in the psoriatic skin 
Subsequently, the distribution of COMP in tissues was analyzed using immunofluorescence 
staining. In line with previous reports, COMP was detected in the papillary dermis of healthy 
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skin. In psoriatic non-lesional samples, COMP deposition extended deeper into the dermis and 
formed a more even and continuous layer than observed in healthy samples. In contrast, COMP 
deposition in lesional skin extended to the upper part of the reticular dermis and exhibited a 
discontinuously scattered distribution. 
4.3. COMP mRNA expression is elevated in non-lesional fibroblasts 
Because skin fibroblasts are the major producers of COMP protein, we examined the mRNA 
expression of COMP in primary dermal fibroblasts derived from healthy and psoriatic non-
lesional skin and detected elevated COMP mRNA expression in non-lesional fibroblasts. 
4.4. COMP co-localization with β1-integrin of basal keratinocytes and EDA+FN is 
increased and with LAMA1 is decreased in non-lesional psoriatic skin 
COMP is known to interact with several members of the integrin cell-surface receptor 
family, including α5β1-integrin, whose expression increases together with EDA+FN in non-
lesional skin, possibly due to damaged BM. To investigate the possible interactions of COMP 
with proteins in the DEJ that have been altered, confocal microscopic analysis with dual 
immunofluorescence staining was applied and consecutive sections of the appropriate area were 
analyzed.  
To determine whether COMP accumulation at the DEJ allows interaction with basal 
epidermal keratinocytes, COMP and β1-integrin co-immunofluorescence staining was applied. 
In the papillary dermis, COMP staining partially co-localized with the β1-integrin from basal 
keratinocytes in healthy and non-lesional skin. However, the co-localization of the two proteins 
was most prominent in psoriatic non-lesional skin.  
LAMA1 is a component of the BM laminin layer, which is fragmented and occasionally 
completely missing in non-lesional psoriatic skin. Therefore, to examine whether the damaged 
BM of non-lesional skin allows the interaction of COMP and β1-integrin, LAMA1–COMP dual 
immunostaining was performed. In non-lesional skin, COMP–β1-integrin double-positive 
regions exhibited a discontinuous LAMA1 staining pattern and the co-occurrence of COMP 
and LAMA1 was significantly lower in non-lesional skin compared to healthy skin. 
In addition, fibronectin has also been reported to interact with COMP; therefore, confocal 
microscopic analysis was also applied to COMP and EDA+FN. In psoriatic non-lesional skin, 
in which co-localization of COMP and β1-integrin was apparent, partial colocalization of 
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COMP and EDA+FN was observed, and the intensity of colocalization was significantly higher 
in non-lesional skin relative to healthy skin. 
4.5. COMP negatively influences keratinocyte proliferation in vitro 
To investigate whether the possible interaction between COMP and β1-integrin influences 
keratinocyte cellular behavior, we first performed an impedance measurement-based, real-time 
cellular analysis of the HPV-KER immortalized keratinocyte cell line. When the culturing plate 
was pre-coated with rhCOMP, cells exhibited reduced CI values in a manner that was dependent 
on COMP concentration compared to cells grown on uncoated surfaces. CI is influenced by 
changes in cell proliferation, viability, morphology and adhesion. To investigate whether the 
proliferation rate of HPV-KER cells was affected, a BrdU cell proliferation assay was 
performed. Pre-coating the surface with a high concentration (10 µg/ml) of rhCOMP resulted 
in significantly reduced proliferation rates at 24 and 72 hours, compared to cells grown on an 
uncoated surface. Cell proliferation of primary NHEK cells was also reduced when the surface 
was coated with 10 µg/ml rhCOMP. 
4.6. COMP negatively influences keratinocyte proliferation via α5β1-integrin in vitro 
To test whether integrins mediate the observed negative effect of COMP on cell 
proliferation, blocking experiments using anti-α5 and anti-β1-integrin polyclonal antibodies 
were performed. Blocking of either α5- or β1-integrin subunit in cells grown on a surface pre-
coated with 10 μg/ml rhCOMP abolished the negative effect of COMP on HPV-KER 
proliferation, whereas blocking either α5- or β1-integrin alone had no negative effect on these 
cells. Similarly, the negative effect of COMP on the proliferation rate of primary NHEK cells 
could also be abolished by blocking COMP, α5- or β1-integrin, as determined with the BrdU 
assay and Ki67 immunofluorescent staining. 
4.7. COMP has a negative effect on skin wound healing by attenuating keratinocyte 
proliferation and by compromising keratinocyte migration and activation in ex 
vivo wound models 
To further study the effect of COMP on keratinocytes, an ex vivo three-dimensional skin 
wound-healing model was applied. Standardized wounded skin samples, with or without 
rhCOMP treatment, and unwounded controls were examined at 72 hours after wounding. 
Immunofluorescent staining revealed COMP-localization on the dermal surface of the injured 
region in COMP-treated wounds, whereas COMP was not detected at the injured region of 
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untreated wounds 72 hours after treatment. By applying Ki67 immunofluorescent staining to 
detect proliferating cells, we found a markedly reduced number of Ki67 positive cells in 
COMP-treated wounds, indicating a decreased rate of proliferation. 
Cell migration processes at the wound edge during the closure of injuries require dynamic 
reorganization of the actin cytoskeleton in the keratinocytes located close to wound margins. 
To visualize these cells, immunofluorescence staining for actin was applied. In wounds not 
exposed to COMP, we found that keratinocytes exhibited high levels of actin expression at 
wound edges, while actin expression at wound edges was markedly decreased in COMP-treated 
wounds, indicating that actin expression was compromised, possibly resulting in a reduction of 
active cell migration. 
KRT17 expression is known to be induced in keratinocytes at wound edges during healing. 
Therefore, we performed KRT17 immunofluorescence staining to further investigate the effect 
of COMP in the ex vivo wound healing model. In rhCOMP-treated wounds, KRT17 expression 
and re-epithelization were reduced and restricted to a smaller proportion of keratinocytes, 
compared to untreated control wounds. This suggests that the presence of COMP compromised 
keratinocyte activation. 
5. DISCUSSION 
In psoriasis, the non-lesional skin contains ECM alterations compared to healthy skin. 
COMP is localized to the papillary dermis of healthy skin and, through its interactions with 
type XII and XIV collagens, contributes to the stabilization of the DEJ. We found that, in 
psoriatic non-lesional skin, COMP is localized to the papillary dermis and, in contrast to healthy 
skin, it forms a continuous, more compact, linear layer beneath the basal keratinocytes. Apart 
from this altered localization, COMP expression was also elevated in dermal fibroblasts from 
psoriatic samples. 
Psoriatic non-lesional skin is more sensitive to stress, and abnormalities at the DEJ and the 
BM are believed to be important in the development of the disease. Interruption of the BM may 
allow ECM components, normally located directly below the BM, to come in direct contact 
with basal keratinocytes. COMP reportedly binds directly to the extracellular domain of β1-
integrin of both cardiomyocytes and cardiac fibroblasts, resulting in the stabilization of β1-
integrin by preventing its degradation and, subsequently, improving cellular survival. In 
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cartilage, COMP mediates chondrocyte attachment and stabilization partially via α5β1-integrin. 
Our confocal microscopic analysis revealed a partial co-localization of papillary dermal COMP 
and β1-integrin in basal keratinocytes, which indicates the possibility of a direct interaction 
between these two proteins in vivo. In non-lesional skin, the α5-integrin subunit is 
overexpressed in the basal layer of the epidermis, in contrast to healthy skin, where it is present 
at low levels or completely missing. Our findings are in line with this observation, as COMP 
and β1-integrin strongly co-localize in psoriatic non-lesional epidermis and expression of both 
are upregulated in non-lesional skin. Moreover, the BM is partially discontinuous in psoriatic 
non-lesional skin, allowing direct interaction. The possibility of this interaction is supported by 
our finding that, in areas where COMP and β1-integrin were found to have strong co-
localization in psoriatic non-lesional skin, the expression of LAMA1, a member of the BM, is 
reduced or completely absent.  
COMP also interacts with α7β1- and αvβ3-integrins. Of these proteins, only α7β1 contains 
a β1-integrin subunit. There is currently no information available about α7β1-integrin 
expression in basal keratinocytes. Thus, we assumed that, if COMP exhibits a strong interaction 
with β1-integrin, its α-subunit is likely to be α5-integrin. In addition to binding to α5β1-integrin, 
a fibronectin receptor, COMP might also bind to the fibronectin protein itself. Furthermore, 
α5β1-integrin–associated fibronectin and EDA+FN are known to play roles in psoriasis 
pathogenesis. Enriched expression of α5β1-integrin and EDA+FN in non-lesional skin are 
thought to be due to the incompleteness of the laminin layer. Our confocal microscopic analysis 
revealed partial co-localization of COMP and EDA+FN in non-lesional skin. These results 
suggest that, in addition to interacting with EDA+FN, COMP may also affect basal 
keratinocytes via interactions with both the EDA+FN and its receptor, α5β1-integrin. 
Keratinocyte behavior is influenced by ECM proteins through interactions with different cell 
surface integrins, and connection of basal keratinocytes to the altered BM could enhance 
proliferation. We analyzed the biological relevance of the interaction of COMP and β1-integrin 
in basal keratinocytes using HPV-KER and NHEK cells in vitro. We found that the presence of 
COMP resulted in reduced keratinocyte proliferation in both cell types and that this affect was 
reversible by blocking COMP with a specific antibody. 
We also analyzed whether the observed negative effect of COMP on keratinocyte 
proliferation involves interaction with α5β1-integrin. By partially blocking the function of the 
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β1- or α5-integrin subunits with specific antibodies, the negative effect of COMP on cell 
proliferation was abolished, suggesting that the negative influence of COMP on keratinocyte 
proliferation involves α5β1-integrin.  
Our in vitro findings were also validated in an ex vivo wound model: exogenous COMP 
treatment delayed healing of artificial wounds, and this affect was coupled with reduced 
keratinocyte proliferation and compromised actin expression, both important aspects of wound 
healing. In addition, keratinocyte KRT17 expression, considered a hallmark of normal wound 
healing, was also decreased in the presence of COMP. These results suggest that COMP has a 
negative influence on ex vivo wound healing. Interestingly, in normally healing wounds of 
healthy donors, COMP was hardly detectable when re-epithelialization was complete. 
Similarly, in psoriatic lesions, in which keratinocyte proliferation is abnormally increased, 
COMP was found to be discontinuous or completely absent from the papillary dermis. Although 
there are no data regarding keratinocyte proliferation or migration in wounds of COMP-
deficient mice, in human non-healing wounds, such as venous leg ulcers, the level of COMP is 
reported to be highly elevated. Our findings are in agreement with this observation. 
In conclusion, our study shows that COMP is present at an elevated level in the papillary 
dermis of non-lesional psoriatic skin and that it possibly reduces keratinocyte proliferation via 
the α5β1-integrin. These aspects of COMP contribute to the maintenance of the non-lesional, 
non-hyperproliferative state of psoriatic non-lesional epidermis, despite the overexpression of 
EDA+FN and α5-integrin. Similar interactions may also take place in other skin diseases in 
which non-healing wounds are coupled with massive COMP accumulation. 
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6. SUMMARY 
In psoriasis, the non-lesional skin contains alterations, which affect the DEJ region, where 
the laminin-layer within the BM is discontinuous, as well as the fibronectin splice variant 
EDA+FN and the α5β1-integrin showed increased expression and could be responsible for 
keratinocyte hyperproliferation. COMP can modulate cellular behavior via cell-surface 
receptors. Furthermore, it is part of the papillary dermis of healthy skin, but its expression has 
not yet been studied in psoriatic skin.  
In this study, we found that COMP extended deeper into the dermis and formed a more 
continuous layer in psoriatic non-lesional skin compared to healthy skin, while in psoriatic 
lesions, COMP showed a partially discontinuous deposition at the DEJ. Co-localization of 
COMP was increased together with basal keratinocyte β1-integrin and EDA+FN and decreased 
with LAMA1 in non-lesional psoriatic skin. In in vitro models, the presence of exogenous 
COMP decreased the proliferation-rate of keratinocytes and this proliferation suppressing effect 
was diminished by the blocking of the α5β1-integrin. 
Finally, our results suggest that interacting with α5β1-integrin of non-lesional basal 
keratinocytes through the discontinuous LAMA1 in psoriatic non-lesional skin, COMP may 
contribute to restrain the proliferation rate of non-lesional basal keratinocytes, thus maintaining 
the non-lesional, non-hyperproliferative state of psoriatic non-lesional epidermis despite the 
overexpression of EDA+FN and α5β1-integrin. The antiproliferative effect of COMP is likely 
to be relevant to other skin diseases in which chronic non-healing wounds are coupled with 
massive COMP accumulation.   
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